Clinical Trial Update: Trial With Gemcitabine and Rapamycin in Second Line of Metastatic Osteosarcoma [Phase 2]

View source ↗

Summary

This update notes the completion of a Phase 2 trial evaluating the combination of gemcitabine and rapamycin as second-line therapy for metastatic osteosarcoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteosarcoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Rapamycin (sirolimus)

Snippet

Sponsor: Broto, Javier Martín, M.D. | Conditions: Osteosarcoma | Phase 2 | Status: COMPLETED